Original ArticlesPhase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Under an Elsevier user license
open archive
Keywords
Phase II
Non-small cell lung cancer
Enzastaurin
Pemetrexed
Cited by (0)
Alberto Chiappori is a member of the speaker's bureau for Eli Lilly and Company (Lilly) and has received honorarium and travel expenses; Gerold Bepler is a consultant and has received research funding from Lilly; Jean-Charles Soria has been a consultant for Lilly; Martin Reck has received honoraria as a member of an advisory board and as a speaker for Lilly-sponsored symposia; Joachim von Pawel is a member of the advisory board for Boehringer Ingelheim; Asavari Wagle, Astra M. Liepa, Yan Daniel Zhao, Nadia Chouaki, and Neill Iscoe are employees and stockholders in Lilly. Other authors have no relevant financial disclosures for this manuscript.
Presented at the 13th World Conference on Lung Cancer, San Francisco, CA, July 30–August 4, 2009.
Copyright © 2010 International Association for the Study of Lung Cancer. All rights reserved.